ArticleTranslational lung cancer research2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboringAnnals of medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine kinase inhibitor (TKI)-targeted therapy has significantly improved the quality life of patients with advanced non-small cell lung cancer (NSCLC). Smoking is the main pathogenic factor of lung cancer. A number of the studies have analyzed smoking patients and nonsmoking patients as grouping factors, but few have examined the characteristic gene mutations in these groups. This study thus aimed to examine the characteristic pathogenic mutations in smokers with NSCLC. Methods: A total of 302 smokers with stage IIIB-IV NSCLC were recruited from Jilin Cancer Hospital between June 2022 and July 2024. Gene sequencing was performed on tumor tissues, pleural effusion cells, and plasma via next-generation sequencing (NGS). Results: A total of 302 smoking patients were enrolled in the study, with the median age of 65 years, among whom 77.48% (234/302) were males and 22.52% (68/302) were females. The sample types included tissue 237 samples, 55 plasma samples, and 10 pleural effusion samples. The mutation rates of common driving genes in smoking patients were as follows: Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.